Lutikizumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Rheumatoid ArthritisAtopic DermatitisUlcerative ColitisPsoriatic ArthritisHidradenitis SuppurativaCrohn's Disease

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

1

Lutikizumab

AbbVie

Phase 3

12

Rituxan

Roche

Preclinical

613

Actemra

Roche

Preclinical

1184

Cimzia

UCB

Preclinical

305

Simponi

Johnson & Johnson

Preclinical

196

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

147

Ilaris

Novartis

Preclinical

38

Celexa

AbbVie

Preclinical

19

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

710

Cataflam

Novartis

Preclinical

—Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa3 trials

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Active, not recruiting·AbbVie·Phase 2·NCT05139602·210 enrolled

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

Recruiting·AbbVie·Phase 2·NCT06524635·60 enrolled

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting·AbbVie·Phase 3·NCT06468228·1,400 enrolled

Ulcerative Colitis1 trial

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

Active, not recruiting·AbbVie·Phase 2·NCT06257875·156 enrolled

Tics1 trial

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Completed·AbbVie·Phase 1·NCT06067568·50 enrolled

Psoriatic Arthritis1 trial

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Recruiting·AbbVie·Phase 2·NCT06865105·120 enrolled

Atopic Dermatitis1 trial

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

Active, not recruiting·AbbVie·Phase 2·NCT06718101·83 enrolled

2 more indications

Rheumatoid Arthritis1 trial

A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis

Recruiting·AbbVie·Phase 2·NCT06972446·180 enrolled

Crohn's Disease1 trial

A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

Recruiting·AbbVie·Phase 2·NCT06548542·540 enrolled

Details

Drug Info

Related News